Pixium Vision (PAR: PIX)

Last close As at 24/02/2024

EUR0.15

−0.04 (−21.05%)

Market capitalisation

EUR1m

Pixium Vision develops bionic vision systems for patients with severe vision loss. Its lead product, Prima, is a wireless sub-retinal implant system designed for Dry-ARMD. The company has completed a human feasibility study for Prima in Europe and expects to start implantations in a US feasibility study in H119.

Latest Insights

View More

Healthcare | Flash note

Pixium Vision — Safeguard proceedings underway

Healthcare | Update

Pixium Vision — Shareholder loan extends runway

Healthcare | Flash note

Pixium Vision — Breakthrough designation provides validation

Pixium-Vision_resized

Sector

Healthcare

Balance Sheet

Forecast net debt (€m)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (6.9) (92.8) (97.1)
Relative (13.0) (92.8) (97.3)
52 week high/low €0.2/€0.0

Financials

Edison Investment Research is terminating coverage on Kinarus Therapeutics (KNRS), Numis Corporation (NUM), EMIS Group (EMIS), Pixium Vision (PIX) and Treatt (TET). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
Previously published reports can still be accessed via website

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (fd) (c) P/E (x) P/CF (x)
2021A 2.7 (9.7) (10.9) (23.06) N/A N/A
2022A 2.0 (11.5) (10.3) (21.09) N/A N/A
2023E N/A N/A N/A N/A N/A N/A
2024E N/A N/A N/A N/A N/A N/A

Further insights

insight

Healthcare

Retinal implants

Analyst of the week

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Read latest

Thematics

thematic

Healthcare

Deutsches Eigenkapitalforum (EKF) 2023 healthcare

volition01

thematic

Healthcare

VolitionRx – Decoding the DNA of cancer 

thematic

Healthcare

ASCO 2023 key takeaways

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free